Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts

While Amgen will try to ward off biosimilar competition to Neulasta, the pharmaceutical giant will struggle to maintain market share in the long run, according to an updated financial forecast Leerink released Monday.